Last
Update:
July 21, 2011
 Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
6th IAS Conference on HIV Pathogenesis,
Treatment
and Prevention |
|
-
POSTER
Clinical validation of standard population-based and deep sequencing
genotypic tropism tests using virological
response to a short-term monotherapy maraviroc exposure
A. Gonzalez-Serna, R.A. McGovern, R. Harrigan, et al
Poster
Abstract
-
POSTER
Natural resistance to Maraviroc in
HIV-infected patients: study by genetic forms and co-receptors usage
Y. Vega, A. Fernandez-García, E. Delgado, et al
Poster
Abstract
-
POSTER
Immunological efficacy of maraviroc (MVC)
as intensification strategy in HIV-infected patients (pts) failing CD4
recovery on virologically-suppressive HAART
S. Rusconi, E. Colella, F. Adorni, et al
Poster
Abstract
-
POSTER
Study of the immunomodulant effect of darunavir and maraviroc on apoptosis of
PBMC
I. Sauzullo, F. Mengoni, A. Ermocida, et al
Poster
Abstract
-
POSTER
Maraviroc 150 mg QD plus lopinavir/ritonavir, a NRTIs-sparing regimen for
naïve patients: preliminary 48-weeks
results
S. Nozza, L. Galli, A. Antinori, M.
et al
Poster
Abstract
-
POSTER
Persistence of antiretroviral regimens including raltegravir, maraviroc,
darunavir and/or etravirine in clinical practice
I. Castillo Romera, N. Trovato López, S. Plata Paniagua, et al
Poster
Abstract
-
POSTER
No maraviroc (MVC) concentration exposure-response relationship identified for
48-week efficacy (< 50 copies/mL) in treatment-experienced patients in the
MOTIVATE studies when undetectable MVC concentrations were accounted for
separately from MVC concentrations
L. McFadyen P. Jacqmin, B. Weatherley, et al
Poster
Abstract
-
POSTER
Maraviroc (MVC) pharmacokinetics (PK) in CCR5-tropic HIV-1-infected children
aged 2-< 18 years: preliminary results from study A4001031
M. Vourvahis, L. McFadyen, B. Duncan, et al
Poster
Abstract
-
POSTER
Safety and efficacy of maraviroc (MVC) in CCR5-tropic HIV-1-infected children
aged 2 to < 18 years
C. Giaquinto, J. Fourie, I. Mitha, et al
Poster
Abstract
-
POSTER
Efficacy of maraviroc (MVC) administered once daily (QD) or twice daily (BID)
with boosted protease inhibitors (bPIs) to treatment-experienced patients
S. Taylor, J. Arribas, C.-F. Perno, et al
Poster
Abstract
-
48-week results
of a dual-therapy regimen of once-daily maraviroc (MVC) 150 mg in
combination with
ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine/tenofovir
(FTC/TDF) + ATV/r in
|treatment-naïve (TN) patients infected with CCR5-tropic H
S. Portsmouth, C. Craig, A. Mills,
et al
Abstract
-
Maraviroc (MVC) reduces liver stiffness (LS) in HIV-hepatitis C (HCV)
co-infected patients
P. Nasta, F.
Gatti, F. Borghi, et al
Abstract
-
Maraviroc-resistant subtype B primary HIV-1 induced in vitro selection
became highly sensitive to anti-gp120
neutralizing antibodies and
autologous plasma IgG under high concentrations of the CCR5 inhibitor
K. Yoshimura, S. Harada, A. Hamaji, S. Matsushita
Abstract
-
HIV-1 escape from
the CCR5 antagonist maraviroc associated with an altered and less
efficient mechanism
of gp120-CCR5
engagement that attenuates macrophage tropism
M. Roche, M.R. Jakobsen, J. Sterjovski, et al
Abstract
-
Next generation
deep sequencing to evaluate viral tropism in HIV-1 patients exposed to
maraviroc add-on therapy
for eight days
R.A. McGovern, A.F.Y. Poon,
et al
Abstract
-
Plasma viral load underestimates the antiviral efficacy of maraviroc
V. Kramer, S. Schader, M. Oliviera, et al
Abstract
-
Effect of maraviroc
treatment in a patient with a dual-tropic viral population
L. Mainetti, A. Galli, A. Pignataro, et al
Abstract
-
Pharmacokinetics of
maraviroc administered at 150 mg QD in association with lopinavir/ritonavir as a
part of a
novel NRTI-sparing regimen in naïve patients
S. Bonora, S. Nozza, D. Gonzalez de Requena, et al
Abstract
-
Prevalence of X4-tropic
viruses in HIV-1-infected patients according to CD4 counts, viral load and
antiretroviral
exposure
E. Seclén, V. Soriano, M.M. Gonzalez, et al
Abstract
-
Human primary
macrophages and lymphocytes are differently infected by HIV-1 dual/mixed
variants: study of
susceptibility to CCR5- and CXCR4-inhibitors
E. Balestra, M. Surdo, P. Saccomandi, et al
Abstract
-
Maraviroc-resistant
subtype B primary HIV-1 induced in vitro selection became highly sensitive to
anti-gp120 neutralizing antibodies and autologous plasma IgG under high
concentrations of the CCR5 inhibitor
K. Yoshimura, S. Harada, A.
Hamaji, et al
Abstract
-
A WEEK-IN-REVIEW
FEATURED REPORT
POSTER
Genotypic Analysis of Cellular HIV V3 DNA
to Predict Virologic Response to Maraviroc:
Performance of Population-based and 454 Deep V3 Sequencing
L Swenson, R McGovern, I
James, et al
PDF Poster
Abstract
-
POSTER
MVC 300 mg Once Daily + DRV/RTV 800/100 mg Once Daily Provides MVC Trough
Concentrations Comparable
to Trough Concentrations in HIV-1 Patients Taking MVC 300 mg Twice Daily +
TVD: Implications for Phase 3 Studies
Stephen Taylor, N Dufty, J
Watson, et al 18 CROI
PDF Poster
Abstract
XVIII International AIDS Conference
|
|
-
POSTER
Maraviroc in treatment-experienced patients
G. Sterrantino, M. Trotta, P.G. Rogasi, et al
PDF Poster
Abstract
-
POSTER
Duration of antiretroviral regimens
including Raltegravir, Maraviroc, Darunavir and/or Etravirine in
clinical practice
I. Castillo Romera, A. Ais Larisgoitia, V. Escudero Vilaplana, et al
PDF Poster
Abstract
-
POSTER
Low risk of malignancy with maraviroc in treatment-experienced (TE) and
treatment-naïve (TN)
patients across the maraviroc clinical development program
S. Walmsley, R. Campo, J. Goodrich, et al
PDF Poster
Abstract
-
POSTER
Duration of antiretroviral regimens including
Raltegravir, Maraviroc, Darunavir and/or Etravirine in
clinical practice
I. Castillo Romera, A. Ais Larisgoitia, V. Escudero Vilaplana, et al
PDF Poster
Abstract
- POSTER
Efficacy and safety of MVC in treatment-experienced over-sixty patients
G. Sterrantino, B. Borchi, M. Trotta, et al
PDF Poster
Abstract
- POSTER
Virologic outcome by V3 loop genotypic population sequencing and 454 'deep
sequencing' in clade B
and non-B virus in MERIT at 48 and 96 weeks
S. Portsmouth1, D. Chapman1, M. Lewis, et al
PDF Poster
Abstract
- POSTER
Use of genotypic and maraviroc (MVC) clinical trial data to develop
statistical models for predicting r
esponse in a treatment-experienced (TE) population
P. Biswas, D. Chapman, X. Zhong, et al
PDF Poster
Abstract
- POSTER
Effect of 24 weeks intensificaction with a CCR5-antagonist on the decay of
the HIV-1 latent reservoir
L. Díaz, C. Gutierrez, C. Page, et al
PDF Poster
Abstract
- POSTER
Effect of a CCR5 antagonist in immune activation in highly suppressed
HIV-1 infected patients
A. Vallejo1, L. Diaz, M. Abad, et al
PDF Poster
Abstract
-
Maraviroc
containing regimen suppress cerebrospinal fluid HIV replication in HIV-1
infected patients
with neurological symptoms
G. Melica, A. Canestri, G. Peytavin, et al
Abstract
-
Clinical
outcome of HIV tropism testing and Maraviroc regimens - 48 weeks follow-up
H. Knechten, F. Wiesmann, E. Wolf, et al
Abstract
-
Hard rescue:
prospective study of effectiveness and safety of new drugs (Darunavir-DRV,
Etravirina-ETR,
Raltegravir-RTG andMaraviroc-MVC) in the last four years (2006-2009)
H. Azkune Galparsoro,.A. Iribarren Loyarte, M.J. Aramburu Bengoechea, et
al
Abstract
-
In vivo
synergistic activity of maraviroc and raltegravir in the reduction of HIV
proviral burden in
circulating reservoirs
C. Tommasi, E. Nicastri, I. Abbate, et al
Abstract
-
mDAPTA, a
potent CCR5 receptor blocker, prevents viral recovery from CD8-depleted
patient PBMCs
with VL< 50 background
L. Agrawal, O. Ducoudret, N. Baichoo, et al
Abstract
-
Detection of
CXCR4-using variants in circulating and proviral HIV quasispecies from
patients treated
with CCR5
antagonist by ultra-deep pyrosequencing
I. Abbate, G. Rozera, C. Tommasi, et al
Abstract
-
Maternal-fetal
pharmacokinetics of a single intrapartum dose of maraviroc in rhesus
macaques
M. Winters1,, K. Van Rompay, A. Kashuba,,et al
Abstract
-
Safety and
immunovirological activity of once daily maraviroc (MVC) in combination
with
ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine
200mg/tenofovir 300mg QD
(TDF/FTC) +
ATV/r in treatment-naïve patients infected with CCR5-tropic HIV-1 (Study
A4001078):
A week 24
planned interim analysis
A. Mills, D. Mildvan, D. Podzamczer, et al
Abstract
|
-
POSTER
Mechanisms of Virologic Failure with Maraviroc in Treatment Naïve HIV-1
Infected Patients
through 96 weeks
C Craig, J Heera, M
Lewis, et al
PDF Poster
Abstract
-
POSTER
Maraviroc Intensification for Suboptimal CD4+ Cell Response
Despite Sustained Virologic
Suppression: ACTG 5256
T Wilkin, C Lalama, A
Tenorio, et al
PDF Poster
Abstract
-
POSTER
Genotypic Analysis of the HIV-1 gp120 V3 Loop for Treatment Experienced
Patients Enrolled
into the MOTIVATE Studies and Who Received Maraviroc + Optimized
Background Therapy
M Lewis, P Simpson, C
Delogne, et al
PDF Poster
Abstract
-
POSTER
Maraviroc Levels in Cerebrospinal Fluid (CSF) and Seminal Plasma from
HIV-Infected Patients
J Manuel Tiraboschi, J
Curto,
J Niubo,et
al
PDF Poster
Abstract
-
POSTER
The
Antiviral and Immunological Effects of Intensification of Suppressive ART
with
Maraviroc, a CCR5 Antagonist
T Evering S
Mehandru, M Poles, et al
PDF Poster
Abstract
-
POSTER
Solute Carrier Organic Anion Transporter 1B1 (SLCO1B1) Mediates Transport
of Maraviroc
Using a X. leavis Model
M Siccardi D Moss, W-S
Kwan, et al
PDF Poster
Abstract
-
POSTER
Effect in vitro of CCR5 Antagonists on Innate Immune System:
Maraviroc Inhibits the Migration
of Neutrophils, Macrophages, and DC
I Sauzullo, M
Lichtner, F Mengoni, et al
PDF
Poster
Abstract
-
POSTER
Two Step Escape Pathway of the HIV-1 Subtype C Primary Isolate Induced by
the in vitro
Selection of Maraviroc
K Yoshimura, S Harada,
S Matsushita
PDF Poster
Abstract
-
POSTER
Down-regulation in vitro of
Matrix Metalloproteinase-9 in Rat Astrocytes by CCR5 Antagonist
Maraviroc: Potential Therapeutical Implication for HIV-associated
Neurologic Disease
P Gramegna, T
Latronico, M T Branà, et al
PDF Poster
Abstract
-
Antiretrovirals for Prevention: Maraviroc Exposure in the Semen and Rectal
Tissue of
Healthy
Male Volunteers after Single and Multiple Dosing
K Brown, K Patterson,
S Malone, et al
-
Maraviroc Fully Inhibits Dual-R5 Virus in Dual/Mixed HIV-1 Infected
Patients
J Symons, S van
Lelyveld, A Hoepelman. et al
Abstract
-
Population-based Sequencing of the V3-loop Is Comparable to the Enhanced
Sensitivity
Trofile
Assay in Predicting Virologic Response to Maraviroc of Treatment-naïve
Patients i
n the
MERIT Trial
R McGovern, W Dong, X
Zhong
Abstract
-
Protection of Rhesus Macaques from Vaginal Infection by Maraviroc, an
Inhibitor of HIV-1
Entry via the CCR5 Co-receptor
R Veazey, T Ketas, J
Dufour, et al
Abstract
5th IAS Conference on HIV Pathogenesis,
Treatment
and Prevention |
|
-
The MERIT study
of maraviroc in antiretroviral-naive patients with R5 HIV-1: 96-week results
J. Heera, P. Ive, M. Botes, et al
Abstract
-
Incidence of
malignancies in treatment-experienced (TE) patients in the MOTIVATE studies
of maraviroc (MVC) + optimized background therapy (OBT): 96 week follow-up
A. Ayoub, S. Walmsley, R. Campo, et al
Abstract
-
Concurrent use of
statins does not influence efficacy of maraviroc in MOTIVATE studies
G. Moyle, N. Rajicic, H. Valdez, et al
Abstract
-
Virologic
suppression on maraviroc in treatment-naïve patients with R5 HIV-1 is similar
to efavirenz at
high baseline viral load, and maraviroc discontinuations for adverse events
are less likely to show drug resistance: 48-week results from the MERI
M. Nelson, A. Lazzarin, G. Di Perri, et al
Abstract
-
Anti-HIV activity
of the candidate microbicide maraviroc, a CCR5 receptor antagonist
P.S. Fletcher, C. Herrera, N. Armanasco, et al
Abstract
|
-
POSTER
CCR5-tropic Resistance to Maraviroc Is Uncommon even among Patients on
Functional Maraviroc
Monotherapy or with Ongoing Low-level Replication
B Jubb, M Lewis, P Simpson, et al
PDF Poster
Abstract
-
POSTER
Mutations in V4 and C4 Regions of the HIV-1 CRF08_BC Envelope Induced by
the in vitro selection of
Maraviroc Confer Cross-resistance to Other CCR5 Inhibitors
K Yoshimura, S
Harada, M Hatada, S Matsushita
PDF Poster
Abstract
-
POSTER
Simultaneous Sustained Release of Maraviroc and Dapivirine from Silicone
Elastomer Vaginal Rings
A Faheem, C McCoy,
MMcBride, et al
PDF Poster
Abstract
Ninth International Congress on Drug Therapy in HIV Infection
|
48th Interscience Conference on Antimicrobial
Agents
and Chemotherapy |
|
Monogram
October 26. 2008
|
6th
IAS Conference
Conference
Archives
Main
New/Newsworthy
